Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in Relapsed and Refractory Small Cell Lung Cancer
NCT00298688Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoint: Disease Control Rate. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00298688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298688.